Respiratory failure & ventilation
Using a targeted metabolomics approach to explore differences in acute respiratory distress syndrome (ARDS) associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia
Authors' conclusion
Different metabolic phenotypes characterize ARDS associated with different viral and bacterial infections.
Study context
- Population
- Patients with ARDS caused by COVID-19, H1N1 influenza or bacterial pneumonia, non-ARDS COVID-19 patients and ICU-ventilated controls
- Participants
- 150 plasma samples
- Comparison
- COVID-19 ARDS vs H1N1 influenza ARDS vs bacterial pneumonia ARDS, compared with non-ARDS COVID-19 patients and ICU-ventilated controls
- Outcome
- Plasma metabolic phenotypes
Methodological detailstargeted metabolomics, quantitative LC-MS/MS and DI-MS/MS
- Targeted metabolomics
- Quantitative LC-MS/MS and DI-MS/MS
Main finding
As reported in the abstract
- Distinct metabolic phenotypes between different infectious causes of ARDS
- C19/A vs H1N1/A: differences in taurine and hypotaurine, pyruvate, TCA cycle metabolites, lysine and glycerophospholipid pathways
- PNA/A vs C19/A: differences in D-glutamine and D-glutamate, arginine, proline, histidine and pyruvate metabolism
- C19/A (ICU) vs C19/P (not ICU): differences in phenylalanine, tryptophan, lysine and tyrosine metabolism
- Significant differences between C19/A, H1N1/A and PNA/A vs ICU-ventilated controls
Original publication
Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia. Crit Care. Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →